


AMENDMENT TO THE CLAIMS

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listings of claims in this patent application.

1. (Currently amended) A composition for treatment of inflammation comprising reduced isoaloha acid (RIAA) and methylxanthine, wherein the RIAA and the methylxanthine are in anti-inflammatory in synergistic amounts having a ratio of 100:1 to 1:100 and wherein said composition comprises from 0.5 to 10000 mg of said RIAA ratio having a combination index (CI) of less than 1.
2. (Previously Presented) The composition of claim 1, wherein the RIAA is derived from hops.
3. (Previously Cancelled)
4. (Previously Presented) The composition of claim 1, wherein said RIAA is a member of Genus A having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃.

5. (Previously Cancelled)
6. (Previously Presented) The composition of claim 1, wherein said RIAA is a member selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone,

dihydro-adhumulone.

7. (Original) The composition of claim 1, wherein said methylxanthine is selected from caffeine; theobromine; theophylline; aminophylline; doxofylline; pentoxifylline; 8-oxopentoxifylline; 8-oxolisolifylline; lisofylline; 1-proparagyl 3,7-dimethyl xanthine; 7-proparagyl 1,3-dimethyl xanthine; 3-proparagyl 1,7-dimethyl xanthine; 1,3,7-tripropargyl xanthine; 3-isobutyl-1-methylxanthine (IBMX); 1,3,7-tripropyl xanthine; 7-benzyl-IBMX; 1-propyl 3,7-dimethyl xanthine; 1,3-dipropyl 7-methyl xanthine; 1,3-dipropyl 7-proparagyl xanthine; 3,7-dimethyl 1-propyl xanthine; and 7-allyl 1,3-dimethyl xanthine.

8. (Previously Canceled)

9. (Previously presented) The composition of claim 8, wherein the methylxanthine is caffeine.

10. (Previously Canceled)

11. (Currently Amended) The composition of claim [[+0]] 1, wherein the composition comprises about 50 to 7500 mg of the RIAA.

12. (Previously presented) The composition of claim 1, wherein the composition comprises about 0.001 to 10 weight percent of the RIAA.

13. (Previously presented) The composition of claim 12, wherein the composition comprises about 0.1 to 1 weight percent of the RIAA.

14. (ORIGINAL) The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

15. (ORIGINAL) The composition of claim 1, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.

16-32. (Previously Cancelled)

33. (New) The composition of claim 1, wherein the RIAA and the methylxanthine are in a ratio of about 100:1 to about 1:100.

34. (New) The composition of claim 1, wherein the composition comprises about 0.5 to 10,000 mg of the RIAA.